Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alnylam Pharmaceuticals, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Alnylam Pharmaceuticals, Inc. trades at $321.17 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | ALNY | |
|---|---|---|
Market Cap | $4.49B | $42.94B |
Sector | Health | Health |
52-Week High | $28.06 | $491.22 |
52-Week Low | $20.06 | $278.09 |
Enterprise Value | $3.69B | $41.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
